Market Newsdesk

SANTA BARBARA, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) — AppFolio (NASDAQ:APPF), the technology leader powering the future of the real estate industry, announced that PURE HomeRiver Property Management has renewed its commitment to AppFolio, establishing it as PURE HomeRiver’s single platform of choice.

Formed through the merger of PURE Property Management and HomeRiver Group, PURE HomeRiver now operates in 35 states. The company has run on AppFolio since 2020 and upgraded to AppFolio Plus in 2022 as its portfolio and footprint expanded. The renewal aims to consolidate the 40,000+ properties PURE HomeRiver manages today onto a single platform, with capacity to support the company’s anticipated growth to 60,000.

“We’ve been dedicated to unifying operations and standardizing processes to create simplified resident, owner, and manager experiences that deliver results,” said Joseph Polverari, Co-founder and CEO of PURE HomeRiver. “In building our technology stack to support that scale, AppFolio was the only clear option for the phase we’re in. One source of truth clarifies the path to performance across every market we’re in today, and in the future.”

“PURE HomeRiver has grown through the same discipline we see in the strongest operators: one platform, one source of truth, so performance doesn’t slow down as the portfolio expands,” said Marcy Campbell, Chief Revenue Officer at AppFolio. “As they scale toward managing 60,000 properties, AppFolio is the constant. That’s the kind of partnership we’re building with operators at every stage of growth.”

As real estate operators consolidate their technology stacks
to drive greater impact across their portfolio, more are choosing AppFolio as the platform they build on for the long term, freeing their teams to focus on the outcomes that matter most to residents, owners, and investors.

About PURE HomeRiver Property Management

PURE HomeRiver is the nation’s largest third-party property management company for single-family rental (SFR) properties. Formed through the merger of PURE Property Management and HomeRiver Group, the company manages more than 40,000 properties across 35+ states.  Led by a team of experienced industry leaders and seasoned technology innovators, PURE HomeRiver combines national scale with local expertise and proprietary AI-native technology to balance investor success with resident satisfaction, creating simplified experiences that deliver results. Learn more at www.purehomeriver.com.

About AppFolio

AppFolio is the technology leader powering the future of the real estate industry. Our innovative performance platform and trusted partnership enable our customers to connect communities, increase operational efficiency, and grow their business. For more information about AppFolio, visit appfolio.com.

Media Contacts

For PURE HomeRiver: [email protected]
For AppFolio: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0ee3d025-bd92-4f4f-a75b-d8be05b4a24c

MCLEAN, Va., Aug. 26, 2026 (GLOBE NEWSWIRE) — Cycurion, Inc. (NASDAQ: CYCU) (“Cycurion” or the “Company”), a leading cybersecurity solutions provider, announced today that it will effect a reverse stock split of its common stock at a ratio of one-for-eight (the “Reverse Stock Split”). The Reverse Stock Split will become effective at August 28, 2026, and the Company’s common stock will begin trading on a split-adjusted basis on The Nasdaq Global Market at the market open on August 28, 2026, under the existing trading symbol “CYCU.” A new CUSIP number, 95758L404, has been assigned to the Company’s common stock in connection with the Reverse Stock Split.

On August 13, 2026, the Company’s board of directors approved the implementation of the Reverse Stock Split. At the Company’s 2026 annual general meeting of stockholders held on July 23, 2026, the Company’s stockholders approved a proposal to effect one or more reverse stock splits at a ratio ranging from 3:1 to 75:1, inclusive, with an aggregate ratio not to exceed 250:1, as described in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on June 30, 2026, as amended. Such stockholder approval became effective on July 23, 2026.

The Reverse Stock Split is intended to, among other things, assist the Company in maintaining compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market.

When the Reverse Stock Split becomes effective, every eight shares of the Company’s common stock then issued and outstanding will be combined into one share of common stock, without any change to the par value per share and without any change in the total number of authorized shares of common stock. The number of issued and outstanding shares of common stock will be reduced from approximately 25,840,335 shares to approximately 3,230,041 shares. The Reverse Stock Split will not affect any stockholder’s percentage ownership interest in the Company, except for minor changes that may result from the treatment of fractional shares.

No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive a fractional share will receive a cash payment (without interest and subject to applicable withholding taxes) equal to the fractional share interest multiplied by the closing price of the Company’s common stock on The Nasdaq Global Market on the trading day immediately preceding the effective date of the Reverse Stock Split.

Stockholders holding share certificates will receive instructions from Equiniti Trust Company, LLC, the Company’s transfer agent, regarding the exchange of shares. Stockholders who hold their shares in brokerage accounts or in “street name” will have their positions automatically adjusted to reflect the Reverse Stock Split and will not be required to take any action.

Proportionate adjustments will be made to all outstanding equity-based awards and securities, including warrants, stock options, restricted stock awards, and convertible securities, to reflect the Reverse Stock Split. These adjustments will affect the number of shares issuable and/or the applicable exercise or conversion prices, as appropriate.

Additional information about the Reverse Stock Split can be found in the Company’s definitive proxy statement furnished to the SEC on June 30, 2026, a copy of which is available at www.sec.gov.

About Cycurion, Inc.

Based in McLean, Virginia, Cycurion (NASDAQ: CYCU) is a forward-thinking provider of IT cybersecurity solutions and AI, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its AI-enhanced ARx platform and expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies, Cloudburst Security, and Cycurion Innovation, Inc., Cycurion serves government, healthcare, and corporate clients committed to securing the digital future.

More info: www.cycurion.com

Forward-Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the operations and prospective growth of Cycurion’s business.

Certain statements in this press release that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Cycurion and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to, the outcomes of the Company’s investigations, any potential legal proceedings, or the future performance of the Company’s stock. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K filed by Cycurion with the U.S. Securities and Exchange Commission. Cycurion anticipates that subsequent events and developments may cause its plans, intentions, and expectations to change. Cycurion assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Cycurion’s plans and expectations as of any subsequent date.

Cycurion Investor Relations:

(888) 341-6680
[email protected]

Cycurion Media Relations:

(888) 341-6680
[email protected]

Sunnyvale, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) — Actelis Networks, Inc. (OTCQB: ASNS), a market leader in cyber-hardened, rapid deployment networking solutions for IoT, military, government, and broadband applications, participated recently in AFCEA TechNet Augusta, one of the premier U.S. defense and industry events focused on military cyber, network modernization, and “C5ISR” (Command, Control, Computers, Communications, Cyber, Intelligence, Surveillance, and Reconnaissance).

The event brought together organizations and leaders from across the U.S. Army’s communications, cyber, network operations communities, providing a firsthand look at the priorities driving military network modernization efforts.

Throughout the conference, Actelis engaged with representatives from across Army organizations, federal systems integrators, and technology partners in discussions aimed at supporting mission-critical communications infrastructure. A common theme was echoed; Actelis can assist the Army’s goal to modernize communications and network infrastructure faster, make them more secure and cost-effective, by making maximum use of existing assets and infrastructure. This engagement comes amid a sharp expansion in federal investment in network modernization: the U.S. Department of Defense has requested $42.7 billion in fiscal year 2026 funding for C5ISR-related programs alone, an 11.4% increase over fiscal year 2025.¹

Actelis’ solutions, delivering fiber-grade performance over existing wireline infrastructure, was identified as a practical approach for supporting the military evolving operational requirements, while reducing deployment complexity and dependence on new infrastructure construction.

The event also strengthened Actelis’ relationships with systems integrators and technology partners serving defense customers. Discussions explored opportunities to support Army and broader Department of War networking initiatives, including base modernization projects, secure communications infrastructure, and mission-critical connectivity requirements.

“What’s encouraging is how practical the conversations are now,” says Jason Chasse, VP of Federal and Military Sales at Actelis. “We are solving real networking challenges that military organizations are facing today, in hours, days and weeks versus outdated practices taking months and years to complete. The cost savings are dramatic, but our ability to provide secure network connectivity in such a short period of time to support the Army’s mission is what separates Actelis from other traditional solutions. We look forward to expanding our support of defense initiatives across all DoW organizations, federal system integrators and industry partners in the future,” said Chasse.

About Actelis Networks, Inc.
Actelis Networks, Inc. (OTCQB: ASNS) is a market leader in hybrid fiber, cyber-hardened networking solutions for rapid deployment in wide-area IoT applications, including government, ITS, military, utility, rail, telecom, and campus networks. Actelis’ innovative portfolio offers fiber-grade performance with the flexibility and cost-efficiency of hybrid fiber-copper networks. Through its “Cyber Aware Networking” initiative, Actelis also provides AI-based cyber monitoring and protection for all edge devices, enhancing network security and resilience. For more information, please visit www.actelis.com.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements. All forward-looking statements speak only as of the date of this press release. You should not place undue reliance on these forward-looking statements. Although we believe that our plans, objectives, expectations and intentions reflected in or suggested by the forward-looking statements are reasonable, we can give no assurance that these plans, objectives, expectations or intentions will be achieved. Forward-looking statements involve significant risks and uncertainties (some of which are beyond our control) and assumptions that could cause actual results to differ materially from historical experience and present expectations or projections. Actual results may differ materially from those in the forward-looking statements and the trading price for our common stock may fluctuate significantly. Forward-looking statements also are affected by the risk factors described in the Company’s filings with the U.S. Securities and Exchange Commission. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

Investor Relations Contact

Arx Investor Relations
North American Equities Desk
[email protected]

¹ U.S. Department of Defense FY2026 budget request for C5ISR-related programs totals $42.7 billion, an 11.4% increase over FY2025. Frost & Sullivan, “US C5ISR Funding Reaches $42.7 Billion as AI, Open Architectures, and Next-Generation Technologies Reshape Defense Modernization,” June 18, 2026, https://www.prnewswire.com/news-releases/us-c5isr-funding-reaches-42-7-billion-as-ai-open-architectures-and-next-generation-technologies-reshape-defense-modernization-302804766.html.

• JAMA Dermatology publication includes results from VALOR skin-specific secondary endpoints, with rapid and durable improvements seen for brepocitinib 30 mg compared to placebo across multiple dimensions of cutaneous dermatomyositis (DM), including measurements of disease activity, itch, and skin-related quality of life
• In patients with at least moderate itch at baseline, clinically meaningful improvements were observed as early as Week 4 in 54% of brepocitinib 30 mg patients versus 10% with placebo, increasing to 74% versus 33%, respectively, by Week 52
• Nearly half of brepocitinib 30 mg treated patients with moderate-to-severe skin disease at baseline achieved remission-level outcomes by Week 52, with 46% demonstrating “Clear” or “Almost Clear” skin on the Investigators Global Assessment (IGA) and 44% achieving functional skin remission on the Cutaneous Dermatomyositis Activity and Severity Index – Activity Score (CDASI-A), more than two-fold higher than with placebo (22% and 21%, respectively) 
• Results complement the primary efficacy and safety results from the VALOR trial previously published in the New England Journal of Medicine and reinforce brepocitinib’s potential as an important treatment for signs and symptoms of skin disease in dermatomyositis, regardless of muscle involvement

DURHAM, N.C., Aug. 26, 2026 (GLOBE NEWSWIRE) — Priovant Therapeutics announced today the publication in JAMA Dermatology of skin-specific outcomes from the Phase 3 VALOR trial evaluating brepocitinib, a first-in-class oral TYK2 and JAK1 inhibitor, in adults with dermatomyositis (DM). Primary efficacy and safety results from the trial were previously published in the New England Journal of Medicine, including benefit on measures of skin disease, muscle strength, physical function, and steroid-sparing.

“Skin disease is a major and often underappreciated driver of morbidity in dermatomyositis, with an impact on quality of life that exceeds most other inflammatory skin diseases,” said Victoria P. Werth, MD, Professor of Dermatology and Medicine at the Perelman School of Medicine at the University of Pennsylvania, Chief of the Division of Dermatology at the Philadelphia Veterans Administration Hospital, and one of the lead investigators of the Phase 3 VALOR Trial. “The rapid and sustained improvements in cutaneous disease activity and itch seen in the VALOR trial, together with the achievement of functional skin remission for many patients with moderate-to-severe skin disease at baseline, represent a monumental finding for patients with dermatomyositis. These results are particularly meaningful given how difficult cutaneous dermatomyositis manifestations and symptoms have historically been to control with conventional therapies.”

In the analyses published in JAMA Dermatology, brepocitinib 30 mg produced rapid, durable and clinically meaningful improvements across multiple dimensions of cutaneous dermatomyositis, including skin disease activity, itch and skin-related quality of life. Treatment effects were evident as early as Week 4 and sustained through Week 52, with significantly more brepocitinib-treated patients achieving clinically meaningful improvements in skin disease activity and itch, as well as remission-level skin outcomes, compared with placebo. The table below summarizes the results published in JAMA Dermatology:

¹Among all participants
²Among participants with at least moderate skin disease at baseline
³Among participants with at least moderate itch at baseline
⁴Minimal clinically important difference defined as 10 units of improvement

Abbreviations: CDASI-A, Cutaneous Dermatomyositis Disease Area and Severity Index – Activity; CDA-IGA, Cutaneous Dermatomyositis Activity-Investigator’s Global Assessment; PP-NRS, Peak Pruritus-Numerical Rating Scale; Skindex-16, skin-related quality of life

Improvements in skin disease occurred alongside reductions in oral corticosteroid (OCS) use. Among patients receiving OCS at baseline, 61.7% of patients treated with brepocitinib 30 mg tapered to 2.5 mg/day (prednisone-equivalent) or less by Week 52 compared to 34.4% receiving placebo, while 41.7% discontinued OCS altogether compared with 23.4% receiving placebo. These findings support brepocitinib’s potential to deliver meaningful control of skin disease alongside substantial tapering of OCS, an important treatment goal in DM given the cumulative toxicity associated with systemic corticosteroid use.

As previously published in the New England Journal of Medicine, the VALOR trial enrolled a broad, representative DM population including patients with prior history of benign or malignant neoplasm and patients with multiple cardiovascular risk factors. Serious infections in the study were increased in brepocitinib 30 mg compared to placebo; these events resolved with medical management, and brepocitinib treatment was completed in most cases. New or recurrent malignancy, cardiovascular events, and thromboembolic events in the study occurred more frequently in the placebo arm than the brepocitinib 30 mg arm. The brepocitinib safety database across all studies includes over 2,000 patients and subjects and supports a safety profile consistent with the known safety profile of JAK inhibitors.

About the Phase 3 VALOR Study

The VALOR study was a global Phase 3 trial that enrolled 241 subjects with dermatomyositis across 90 sites. Subjects were randomized 1:1:1 to brepocitinib 30 mg, brepocitinib 15 mg, and placebo. Brepocitinib 30 mg demonstrated statistically significant and clinically meaningful improvement compared to placebo on the primary endpoint of Total Improvement Score (TIS) at Week 52. TIS is a composite endpoint of six core set measures of myositis disease activity. Benefit compared to placebo was seen as early as Week 4 and sustained at every visit thereafter through the end of the one-year double-blind treatment period. Brepocitinib 30 mg also demonstrated statistically significant and clinically meaningful improvement compared to placebo on all nine key secondary endpoints evaluated, including measures of muscle strength, skin disease activity, functional disability, and steroid tapering. More than two thirds of brepocitinib 30 mg patients achieved a Total Improvement Score of at least 40 (TIS40), twice the minimum clinically important difference. More than half achieved this TIS40 threshold while also reducing systemic corticosteroid use to ≤2.5 mg/day (prednisone-equivalent). Brepocitinib exhibited a safety profile consistent with the known safety profile of JAK inhibitors, with no new safety signals identified.

About Priovant

Priovant Therapeutics is a biotechnology company dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company’s lead asset is brepocitinib, a first-in-class, selective inhibitor of TYK2 and JAK1. Through selective TYK2/JAK1 inhibition, brepocitinib distinctively suppresses key cytokines linked to autoimmunity—including type I IFN, type II IFN, IL-6, IL-12 and IL-23—with a single, targeted, once-daily oral therapy. Brepocitinib recently generated positive Phase 3 data in dermatomyositis. Brepocitinib is also being evaluated in a Phase 3 program in non-infectious uveitis, a Phase 3 program in cutaneous sarcoidosis, and a Phase 2b/3 program in lichen planopilaris. Priovant Therapeutics is a Roivant (Nasdaq: ROIV) company.

Contacts:

Stephanie Lee: [email protected] 

Image 1 Michael Arbus, CEO of Moomoo Financial Canada and the winner of the Canada’s Top Trader competition, Dinghao Zhang at the Moomoo Store at CF Markville, located in Markham, Ontario, Canada. 

TORONTO, Aug. 26, 2026 (GLOBE NEWSWIRE) — Moomoo Financial Canada has announced the winner of its inaugural Canada’s Top Trader Competition, the country’s first live, real-money national trading competition held in partnership with Nasdaq. Running from June 1 to July 31, 2026, the competition attracted more than 8,000 registered participants from across the country and generated the highest trading activity in Moomoo Financial Canada’s history.

Over two months, investors competed using their own capital in live markets while tracking their performance on a national leaderboard. The competition brought together participants from coast to coast, highlighting Canadians’ growing interest in self-directed investing and financial education.

Following the competition, Dinghao Zhang of Thunderbay, Ontario earned the title of Canada’s Top Trader 2026, achieving a 4,972% return to secure first place among thousands of participants. In recognition of the achievement, the winner’s name will be showcased on the iconic Nasdaq MarketSite billboard in New York City’s Times Square, celebrating Canada’s top trader on one of the world’s most recognizable financial stages.

“This competition surpassed our expectations, bringing together more than 8,000 Canadians from across the country to learn, compete and engage with markets,” said Michael Arbus, Chief Executive Officer of Moomoo Financial Canada. “The overwhelming response and record trading activity demonstrate the growing demand for accessible investing tools and financial education. We are proud to have created an experience that empowered investors of all levels while fostering a strong investing community.”

Dinghao added, “Winning Canada’s Top Trader Competition is an incredible honour. Competing alongside thousands of investors from across the country challenged me to stay disciplined, trust my strategy, and continue learning. I am grateful to have been part of an experience that celebrates investing and inspires more Canadians to build confidence in the markets.”

The strong response to the inaugural competition is setting the stage for the second Canada’s Top Trader Competition, launching this September and running through November 2026. The next edition will once again give Canadians an opportunity to put their trading strategies to the test in live markets while connecting with a growing community of self-directed investors.

The new competition is set to launch on September 1, 2026, and will offer participants a chance to win a new Tesla Model 3. Canadians can begin pre-registration today at https://www.moomoo.com/ca/competition/top-trader2.

Highlights from the Inaugural Competition

• More than 8,000 registered participants
• 40% of participants represented cities such as Toronto and Vancouver
• SpaceX and NVIDIA were the most traded stocks amongst the participants
• Canada’s first live, real-money national trading competition in partnership with Nasdaq
• $1,000,000 CAD prize pool awarded

As Moomoo Financial Canada looks ahead to the second edition, Canada’s Top Trader reflects the company’s ongoing commitment to making investing more accessible through innovative technology, investor education and community engagement. By bringing Canadians together to learn, compete and participate in live markets, the competition aims to foster greater confidence and engagement among today’s self-directed investors.

More details about the second Canada’s Top Trader Competition is available at https://www.moomoo.com/ca/competition/top-trader2.

About Moomoo Financial Canada

Moomoo Financial Canada Inc. is an award-winning trading platform built to democratize access to professional-grade tools, real-time market data, and advanced analytics typically associated with institutional trading environments. Named by Benzinga as the #1 U.S. Stock Trading Platform for Canadians, the platform helps active and self-directed investors see market signals sooner and act with more confidence.

Regulated by the Canadian Investment Regulatory Organization (CIRO) and a member of the Canadian Investor Protection Fund (CIPF), Moomoo Financial Canada Inc. is an affiliate of Futu Holdings Limited (NASDAQ: FUTU), a global fintech company serving more than 30 million users worldwide.

Learn more atwww.moomoo.ca.

Instagram | moomoo_canada
LinkedIn | moomoo_canada

Media Contact:
Carlee Snyder
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c6966643-8df5-447b-b3b7-a6ae951fc0ec

NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has filed a class action suit in the United States District Court for the Southern District of New York against GoDaddy Inc. (“GoDaddy” or the “Company”) (NYSE: GDDY), captioned Johnson v. GoDaddy Inc., et al., Case No. 1:26-cv-07144, on behalf of all persons and entities who purchased GoDaddy common stock during the period September 3, 2025 through February 24, 2026, inclusive (the “Class Period”).

CLICK HERE TO JOIN THE CASE

If you are an investor in GoDaddy Inc. and have suffered losses, you may

CLICK HERE

to contact us. You may also contact Kaplan Fox by emailing

[email protected]

or

[email protected]

or by calling (212) 329-8566.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than October 20, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

The Complaint alleges that throughout the Class Period, the Defendants made false and misleading statements, and omitted information necessary to make the statements not false or misleading at the time they were made, because while the Company represented to investors that its strategy “isn’t to grow customers just for the sake of growing customers” and that “[w]e’ve seen the average order size go up,” the Company had implemented a promotion focusing on short term contracts with smaller valuations, which in turn led to a decrease in total bookings and deceleration of bookings growth for both the fourth quarter and full year 2025.

The Complaint further alleges that on February 24, 2026 after the close of the market, the truth regarding the Company’s promotional discount instituted in the fall of 2025 and its material, adverse effect on total bookings growth was revealed when the Company issued a press release reporting its fourth quarter and full year 2025 financial results with the SEC on Form 8-K (the “Press Release”). The Press Release revealed that total bookings growth had sharply decelerated to 5% in the fourth quarter of 2025.

The Complaint alleges that these disclosures caused the price of GoDaddy common stock to decline from a price of $92.30 per share on Tuesday, February 24, 2026 to a closing price of $79.12 per share on Wednesday, February 25, 2026, a decline of $13.18 per share, or more than 14% on heavier than usual volume.

Plaintiff seeks to recover damages on behalf of the proposed Class and is represented by Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com). Our firm, with offices in New York, Oakland, California, Los Angeles, Chicago, and New Jersey, has decades of experience in prosecuting investor class actions and actions involving violations of the Federal securities laws.

If you have any questions about the action, your rights, or your interests, or would like a copy of the Complaint, please e-mail attorneys Frederic S. Fox ([email protected]) or Donald R. Hall ([email protected]), or contact them by phone, regular mail, or fax:

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
https://www.kaplanfox.com/case/godaddy-inc-investor-alert-learn-more-now/

NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (NASDAQ: ALHC).

CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION

If you are an Alignment Healthcare investor and have suffered losses, or if you have information that could assist in the Alignment Healthcare investigation, you may

CLICK HERE

to contact us. You may also contact Kaplan Fox by emailing

[email protected]

or by calling (646) 315-9003.

On July 8, 2026, news emerged that a former Alignment Healthcare executive had filed a whistleblower complaint alleging the Company engaged in “accounting irregularities” that “artificially inflated” Alignment Healthcare’s previously reported and projected financial results, including “Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“Adjusted EBITDA”), a key non-GAAP financial metric central to the Company’s reported financial performance and executive compensation structure.” According to the lawsuit “millions of dollars in operating expenses had been systematically misclassified as capital expenditures.”

Following this news, on July 8, 2026, the price of Alignment Healthcare stock fell $4.02 per share, or 16.7%, to close at $20.03 per share.

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation’s premier plaintiffs’ securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this investigation, please contact:

CONTACT:

Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
[email protected]

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
[email protected]

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/alignment-healthcare-investigation-learn-more/